Published: 9 July 2022
Author(s): Corrado Campochiaro, Nicola Farina, Alessandro Tomelleri, Roberto Ferrara, Silvia Viola, Chiara Lazzari, Giacomo De Luca, Daniele Raggi, Alessandra Bulotta, Marco Matucci-Cerinic, Andrea Necchi, Marina Garassino, Vanesa Gregorc, Lorenzo Dagna
Section: Original article

In the last decade, immune checkpoint inhibitors (ICIs) have become a therapeutic tool of paramount importance when managing malignancies. ICIs currently represent the standard of care for several advanced cancers [1]. Despite their remarkable efficacy, these agents are associated with the onset of peculiar clinical manifestations called immune-related adverse events (irAEs) [2].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.